Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for CalciMedica Inc. (CALC : NSDQ)

• Company Description    CalciMedica Inc. is a clinical-stage biopharmaceutical company. It focused on developing therapies for life-threatening inflammatory diseases with high unmet need. CalciMedica Inc. is based in LA JOLLA, Calif. Number of Employees: 14

• Price / Volume Information    Yesterday's Closing Price: $1.62 Daily Weekly Monthly 20 Day Moving Average: 27,285 shares Shares Outstanding: 13.97 (millions) Market Capitalization: $22.64 (millions) Beta: 1.24 52 Week High: $5.97 52 Week Low: $1.43 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -7.43% -10.90% 12 Week 4.52% -12.09% Year To Date -54.24% -57.14%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 505 Coast Boulevard South Suite 307 - La Jolla,CA 92037 USA ph: 858-952-5500 fax: - calcimedica@argotpartners.com http://www.calcimedica.com

• General Corporate Information    Officers A. Rachel Leheny - Chief Executive Officer and Director Robert N. Wilson - Chairman Stephen Bardin - Chief Financial Officer Alan Glicklich - Director Frederic Guerard - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 38942Q202 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/11/25 Share - Related Items Shares Outstanding: 13.97 Most Recent Split Date: 3.00 (0.07:1) Beta: 1.24 Market Capitalization: $22.64 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.41 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.64 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.08 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 16.28% vs. Previous Quarter: -5.88% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -171.81 12/31/24 - -146.23 ROA 06/30/25 - - 03/31/25 - -100.43 12/31/24 - -94.70 Current Ratio 06/30/25 - - 03/31/25 - 5.66 12/31/24 - 5.34 Quick Ratio 06/30/25 - - 03/31/25 - 5.66 12/31/24 - 5.34 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 0.78 12/31/24 - 1.07 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.79 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 44.13 12/31/24 - 0.00

Powered by Zacks Investment Research ©